IGHE and asthma: All these data confirm that severe asthma and comorbid CRSwNP represent a distinct phenotype that may benefit from the use of biologic agents, including anti-IgE strategies, as already suggested by Rivero and Liang in their systematic review and meta-analysis on anti-IgE and anti-interleukin 5 (IL5) treatment for CRSwNP [51].